BioSpace News Archive

Simulations Plus, Inc. (Nasdaq: SLP), today announced that it has received a Phase II SBIR NIH grant for the further development and validation of its novel BIOLOGXsym™ platform, which is quantitative systems toxicology (QST) software focused on complex macromolecule liver safety.

Bayer will present a range of new clinical data at the American College of Cardiology’s 71st Annual Scientific Session (ACC.22), being held April 2-4, 2022, in Washington, D.C.

Prestige Biopharma Limited and Vaxine Pty Ltd announced that the two organizations have entered into a memorandum of understanding (MOU) to collaborate on the supply of Vaxine’s COVID-19 Vaccine, Covax-19® (also known as Spikogen®) and on the co-development of COVID-19/influenza combo vaccine.

CellOrigin Inc, a biotech company focusing on iPSC-derived immune cell therapies, announced it secured a new round of investment of ~100 million RMB from Jifeng Ventures, Kunlun Capital, Yinxinggu Capital and Efung Capital.

Delcath Systems, Inc. announced that it will be participating in the Lytham Partners Spring 2022 Investor Conference, via presentation and panel discussion.

Capricor Therapeutics announced that Dr. Linda Marbán, CEO of Capricor, will participate in a panel discussion at the virtual Cantor Fitzgerald Rare Orphan Disease Summit on March 30, 2022.

Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a clinical-stage precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the appointment of Brian Sun, M.S., J.D. as its incoming Senior Vice President and General Counsel, effective as of April 11, 2022.

Mission Bio, Inc., the pioneer in high-throughput single-cell DNA and multi-omics analysis, launched the Tapestri Solution for Solid Tumor Research.

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced the appointment of Jennifer M. Chao to the company’s Board of Directors.

Coherus BioSciences, Inc., beginning at 9:30 a.m. Eastern Daylight Time , is hosting a meeting with analysts and investors to present the Company’s corporate strategy to build a leading innovative immuno-oncology franchise funded with cash generated through net sales of its diversified portfolio of FDA-approved therapeutics.